Serum Testosterone in Women as
Measured by an Automated Immunoassay and a RIA To the Editor: Taieb et al. (1 ) in their recent report in Clinical Chemistry described the relationship of serum testosterone concentrations measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry (ID/GC-MS). Automated immunoassays fared badly, but RIAs agreed well with the ID/GC-MS.
In contrast to our findings, Taieb et al. (1 ) 
Dr. Boudou responds for the authors of the article cited above:
To the Editor: Torjesen and Sandnes briefly summarize our study (1 ) that compared testosterone immunoassays with an isotope-dilution gas chromatography-mass spectrometry (ID/GC-MS) method. They report mean concentrations in female samples lower than ours for the AutoDelfia system and describe two indirect personal observations to explain our 2.5-fold higher values: One is a very rare IgG that reacted with the labeled analyte of a direct isotopic assay from Orion Diagnostica (2 ) , and the other concerned "a much higher frequency of increased concentrations in individual samples caused by interfering substances in the AutoDelfia". It should be stated that before being assayed, all of our samples were selected in a blind manner with respect to previously described criteria (1 ). These samples were not problematic in immunoassays but were evaluated because they corresponded to our daily recruitment.
As noted in our report (1 ) , in 25 of 55 female samples testosterone was Ͻ2.06 nmol/L by ID/GC-MS. These women could be similar to the female patients of Torjesen and Sandnes. The testosterone concentrations measured by the AutoDelfia system were clearly overestimated, as shown in Fig. 3 of our report (1 ) . In addition, in 42 of 55 females, testosterone was lower than the upper limit of the ID/GC-MS range (0.50 -2.55 nmol/L) as measured in normally menstruating women 19 -35 years of age with no evidence of hirsutism, acne, or alopecia and taking no oral contraceptives for at least 6 months before being tested. Hyperandrogenism has been diagnosed in 24 of these 42 females based on an increase in at least one serum androgen concentration at baseline: dehydroepiandrosterone sulfate Ͼ9.50 mol/L; 17-hydroxypregnenolone Ͼ11.50 nmol/L; dehydroepiandrosterone Ͼ38.00 nmol/L; or androstenedione Ͼ7.85 nmol/L. Eighteen of 42 were "normoandrogenic" females. These 42 females had 17-hydroxyprogesterone concentrations within the reference interval. Mean (SD) testosterone measured by ID/ GC-MS was 1.37 (0.56) nmol/L in normoandrogenic females and 1.93 (0.33) nmol/L in females with hyperandrogenism, whereas it was 2.94 (1.77) and 5.30 (1.74) nmol/L, respectively, for these two groups when measured by AutoDelfia. One would expect that if some particular interfering substances were present in the female samples there would be an intriguing individual serum response in some, if not all, of the direct assays tested, but we did not observe this.
AutoDelfia with Immulite 2000 gives the highest mean testosterone values, widely dispersed results, and the highest overestimation, as shown in Fig. 3 of our report (1 ) . This observation confirmed a previous report (3 ) in which serum pools were tested. The use of pools is more favorable to assay performance because interferences in individual samples are diluted. In that study, the testosterone concentrations in the two female pools tested by ID/ GC-MS were 0.74 and 2.67 nmol/L, whereas they were 1.99 and 4.99 nmol/L, respectively, when measured by AutoDelfia (differences of 169% and 87%). In a dilution test, AutoDelfia results were high by 13-176% (3 ).
We accept the possibility of a change in the assay's reagents between our two studies. Many relevant reports have highlighted interferences in immunoassays (4 -7 ) . Interfering substances and factors relating to blood collection (8 ) have been identified by the manufacturers and considered limitations of the assay procedure. We think that most of the sources of errors involved in direct steroid assays are directly related to the assay format, such as the matrix (9 ), the preparation and the purity of the labeled molecule, the specificity of the antibody, the flexibility of the labeled analyte-antibody complex, and assay optimization.
